INHIBIDORES DE LA ENZIMA ADAM17 Y COMPOSICIONES QUE LOS COMPRENDEN PARA EL TRATAMIENTO EFECTIVO DE LA COVID-19
The invention relates to ADAM17 enzyme inhibitor compounds and compositions comprising them for the effective treatment of COVID-19. The administration of the described inhibitors enables the efficient reversal of severe acute respiratory syndrome (SARS) caused by SARS-CoV-2 virus infection, thereby preventing the destruction of lung tissue observed in patients affected by COVID-19 and restoring the patient's normal health condition. The inhibitors and their described compositions were administered parenterally and intranasally, observing the same beneficial effects of the treatment, and reversing the neutrophilia and leukopenia typically observed in patients affected by COVID-19. The invention also relates to the generation of an animal model that can reproduce severe acute respiratory syndrome (SARS) in a manner very similar to that observed in patients affected by COVID-19, enabling the safe evaluation of various substances with potential pharmacological activity for the treatment of COVID-19..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 27. Mai Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
SCHNOOR MICHAEL [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-05-27, Last update posted on www.tib.eu: 2023-09-14, Last updated: 2023-09-22 |
|---|
| Patentnummer: |
WO2022107054 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA013924494 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA013924494 | ||
| 003 | DE-627 | ||
| 005 | 20230929134059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA013924494 | ||
| 035 | |a (EPA)WO2022107054 | ||
| 035 | |a (EPA)81708501 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a SCHNOOR MICHAEL |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a INHIBIDORES DE LA ENZIMA ADAM17 Y COMPOSICIONES QUE LOS COMPRENDEN PARA EL TRATAMIENTO EFECTIVO DE LA COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-05-27, Last update posted on www.tib.eu: 2023-09-14, Last updated: 2023-09-22 | ||
| 520 | |a The invention relates to ADAM17 enzyme inhibitor compounds and compositions comprising them for the effective treatment of COVID-19. The administration of the described inhibitors enables the efficient reversal of severe acute respiratory syndrome (SARS) caused by SARS-CoV-2 virus infection, thereby preventing the destruction of lung tissue observed in patients affected by COVID-19 and restoring the patient's normal health condition. The inhibitors and their described compositions were administered parenterally and intranasally, observing the same beneficial effects of the treatment, and reversing the neutrophilia and leukopenia typically observed in patients affected by COVID-19. The invention also relates to the generation of an animal model that can reproduce severe acute respiratory syndrome (SARS) in a manner very similar to that observed in patients affected by COVID-19, enabling the safe evaluation of various substances with potential pharmacological activity for the treatment of COVID-19. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a VALLE REYES JUAN SALVADOR |4 aut | |
| 700 | 0 | |a LARTEY LARTEY NATHANIEL |4 aut | |
| 700 | 0 | |a VARGAS ROBLES HILDA |4 aut | |
| 700 | 0 | |a VADILLO ROSADO EDUARDO MANUEL |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 27. Mai |
| 773 | 1 | 8 | |g year:2022 |g day:27 |g month:05 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/81708501/publication/WO2022107054A1?q=WO2022107054 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2022 |b 27 |c 05 |
| 951 | |a AR | ||
| 952 | |j 2022 |b 27 |c 05 | ||